Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

The purpose of this study is to evaluate the effectiveness and safety of Pegcetacoplan in patients with C3G and primary IC-MPGN in the real-world setting. This study will also assess biomarkers not routinely measured in clinical practice. Results will support the long-term evaluation of the benefit-risk profile of pegcetacoplan in a broad patient population, informing clinical decision-making.

NCT Number	NCT07746895
Lead Sponsor	Swedish Orphan Biovitrum Collaborators: IQVIA Pty Ltd
Conditions	C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Enrollment	150 participants
Start Date	2026-07-09
Primary Completion	2031-12-31 (estimated)
Study Completion	2032-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-05